May 14, 2025

Semaglutide at Half Dose—Same Effect?

“When care is designed around the patient, lower doses often prove sufficient."

Reuters

May 14, 2025

Prenatal Testosterone: Shaping Children's Fitness?

New study finds maternal testosterone exposure during pregnancy affects physical activity in boys and muscle strength in girls at age 7, with potential implications for long-term cardiovascular health.

Conexiant

May 12, 2025

Delayed Puberty: Diabetes Risk Signal?

"Our results are surprising as delayed puberty is generally considered a benign condition."

Conexiant

May 09, 2025

Applications Are Now Open for the 2025 Integrative Oncology Scholars Program and Integrative Oncology Fellows Program

Applications are now being accepted for the 2025 Integrative Oncology Scholars Program and Integrative Oncology Fellows Program at the University of Michigan in Ann Arbor (https://sites.google.com/vie...

The ASCO Post

May 08, 2025

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 DED Chamber Trial of Reproxalap

In a dry eye chamber trial, Reproxalap was statistically superior (P = .002) to vehicle in primary endpoint of ocular discomfort.

Ophthalmology Management

May 08, 2025

Data Presented at ARVO Highlight Licaminlimab in the Treatment of DED

Anat Galor, MD, MSPH, presented data from the Oculis Phase 2b RELIEF trial that looked at the effects of licaminlimab in patients with signs of DED, and the influence of a genetic marker, the CC genotype of single nucleotide polymorphism rs1800693 in the TNFα receptor gene.

Ophthalmology Management

May 07, 2025

Pancreatitis Prevention: Just a Myth?

A major study finds no benefit from a common surgery long used to prevent pancreatitis.

Reuters

May 07, 2025

Electric Pulse Procedure May Improve T2D

A minimally invasive procedure using electrical pulses in the small intestine shows promise in significantly improving type 2 diabetes, with benefits rivaling gastric bypass surgery.

Reuters

May 06, 2025

Shorter Prostate Radiotherapy Proves Long-Term Match

Two-week radiation treatment for localized prostate cancer delivers equivalent 10-year outcomes to standard 8-week course in a clinical trial.

Conexiant